- The 20th edition of Eco Expo Asia opens today for four days at AsiaWorld-Expo, gathering some 340 exhibitors from 13 countries and regions- The Expo features diverse activities and product technologies in response to the Policy Address, covering three key areas – Circular Economy and Waste Management, Green & Smart Mobility and ESG-related Services- The ‘Experience Sharing Forum on Promoting Environmental Business in Overseas Markets’ will be held tomorrow. Government officials and representatives of quasi-governmental organisations from Belt and Road countries will share strategies for local market development, to help green companies expand their international networksHONG KONG, Oct 28, 2025 - (ACN Newswire via SeaPRwire.com) – The 20th Eco Expo Asia, jointly organised by the Hong Kong Trade Development Council (HKTDC) and Messe Frankfurt (HK) Ltd and co-organised by the Environment and Ecology Bureau of the Government of the Hong Kong Special Administrative Region (HKSAR), opened at AsiaWorld-Expo today and runs until 31 October. Some 340 exhibitors from 13 countries and regions are showcasing innovative green technologies and products, as well as ESG and sustainable solutions. The last day of the Expo, 31 October, will open to the public for free, to encourage sustainable living practices.Yu Huiwen, Vice Minister of the Ministry of Ecology and Environment of the People’s Republic of China; Ding Zhijun, Deputy Director of the Department of Energy Conservation and Comprehensive Utilization, Ministry of Industry and Information Technology of the People’s Republic of China; Tse Chin-wan, Secretary for Environment and Ecology of the Hong Kong SAR Government; HKTDC Executive Director Sophia Chong; and Richard Li, Executive Director of Messe Frankfurt (HK) Ltd, attended Eco Expo’s opening ceremony today.HKTDC Executive Director Sophia Chong said: “This year, we celebrate a significant milestone of the Expo - its 20th edition. This not only marks our commitment to sustainability but also underscores our ongoing mission to develop the ecosystem for driving innovation and collaboration to support the green agenda. Under the theme ‘Green Innovations for Carbon Neutrality’, Eco Expo Asia provides invaluable opportunities for the green industry. This year, once again, we are bringing together leading players from the eco sector to pave the way for a more sustainable future, in alignment with the Hong Kong SAR Government’s net zero goals.”Speaking at the opening ceremony, the Secretary for Environment and Ecology, Tse Chin-wan, said, "In the global journey towards sustainability, Hong Kong serves as a ‘super connector’. With our unique position as an international city within the Guangdong-Hong Kong Macao Greater Bay Area and a bridge between Chinese Mainland and the world, Hong Kong brings together talent, technology, and capital to foster collaboration and scale up green innovation.Global exhibitors gather to showcase innovative environmental technologiesThis year’s Expo brings together 17 pavilions. For the first time, the Environmental Campaign Committee is hosting a pavilion, presenting 22 local green start-ups, alongside a joint government pavilion featuring 11 bureaux and departments, including the Environment and Ecology Bureau. Chinese Mainland delegations from Guangdong, including Guangzhou and Shenzhen, Guangxi, Hunan, Inner Mongolia and Shanghai are also joining the Expo. The ANSO Environmental Technology Industry Alliance, led by the Alliance of National and International Science Organizations for the Belt and Road Regions (ANSO), is making its debut, together with 11 mainland enterprises, showcasing technologies related to water resources and the atmospheric environment, and laying the foundation for future expansion overseas. New overseas pavilions include Italy and South Korea, while Canada, the Netherlands and Norway are returning this year.The Expo is also actively building a platform to support Hong Kong and mainland enterprises to go global and explore new opportunities in green trade, attracting buyers from Japan, Thailand, Indonesia, Malaysia, Singapore, Vietnam, Hungary and Poland to visit and source at the event. For tomorrow’s ‘Experience Sharing Forum on Promoting Environmental Business in Overseas Markets’, the Hong Kong SAR Government has invited government officials and representatives from quasi-governmental organisations from Belt and Road countries to share strategies to develop local markets. In collaboration with the Environment and Ecology Bureau, the Expo extends invitations to government service providers from the Chinese Mainland, as well as from ASEAN and Belt and Road countries, to visit and source green technologies and products.Three major green and smart areas supporting the Policy AddressEnvironmental protection has become a key policy focus in recent years. The Chinese Government recently released guidelines on advancing low-carbon transition and strengthening the development of China’s carbon trading market. This year’s Policy Address highlighted new directions in green policy in Hong Kong, including fostering green and low-carbon living environments, and expediting the application of green technologies. In line with industry development, the Expo brings together a diverse range of green tech, showcasing the latest achievements in Circular Economy and Waste Management, Green & Smart Mobility and ESG-related Services.In Circular Economy and Waste Management, Green AI Technology Limited (Booth No. 3-D38) displays its AI-powered smart sorting bin with real-time waste identification, demonstrating good recycling methods through interactive learning. Dynagreen Environmental Protection Group Co., Ltd (Booth No. 3-E30) showcases its comprehensive waste treatment project, contributing to sustainable urban development.In Green & Smart Mobility, SANY Turbo Fly Machine Limited (Booth No. 6-C26) from Hong Kong and Macao, a subsidiary of SANY Group, a leading equipment manufacturing company in the Chinese Mainland, brings its SANY Mobile Charging Power Station, which can charge two electric trucks simultaneously. CIMC Enric Investment Holding (Shenzhen) Co., Ltd. (Booth No. 3-F14), a leading manufacturer of advanced clean energy equipment, showcases innovative hydrogen and green methanol technology solutions for transportation and storage.The Expo also showcases ESG-related services. Llewellyn and Partners Company Limited (Booth No. 6-D14) displays AutoTwin, a patented AI-powered integrated management platform for the construction industry, which helps reduce building operating costs, time and carbon emissions.  XSIM AI Canada Inc.,(Booth No. 6-C23), a Canadian technology company, empowers wastewater and industrial facilities with its AI-driven system to reduce downtime and lower operational costs, while cutting carbon emissions by up to 30% .Research institutions and start-ups also play a significant role in the Expo. In addition to the return of The Chinese University of Hong Kong (Booth No. 3-G24), Lingnan University (Booth No. 6-A25) and the Hong Kong Polytechnic University Jinjiang Technology and Innovation Research Institute (Booth No. 6-A23) are joining for the first time this year. The Hong Kong Science and Technology Parks Corporation (Booth No. 3-F20) presents start-up afterNATURE (Booth No. 3-F20), which is showcasing its Deep Hexagonal Basin product. This innovation creates habitats for marine life on its surface, helping to preserve coastal biodiversity. Another start-up, Formwork IO (Booth No. 3-F20), exhibits AtmosBrick and is globally debuting AtmosTile at the Expo. These ‘carbon-negative’ building materials are designed to help reduce carbon emissions.Eco Asia Conference brings together industry leaders, focusing on construction and transportation sectorsEco Expo’s highlight event, Eco Asia Conference, began today with the Government Session. Ding Zhijun, Deputy Director of the Department of Energy Conservation and Comprehensive Utilization, Ministry of Industry and Information Technology of the People’s Republic of China, shared the country’s latest environmental policies and trends. Officials from Myanmar, Sri Lanka, the Philippines and other Belt and Road countries also elaborated on their latest green policies and projects. Another session, ‘Revolutionising with Circular Economy: From Waste to Innovative Solutions’, featured experts led by the Business Environment Council, who explored the application of circular economy concepts in business operations. The Hong Kong Circular Built Environment Guidebook is also making its debut at the Conference, providing the latest green guidelines for the construction industry.On the third day of the Expo, on 30 October, the Conference will have two main themes: ‘Building a Sustainable Future: Gearing Towards a Net-Zero Built Environment’ and ‘Green & Smart Mobility – Envisioning the Future of Transportation’. Industry leaders and experts, including Pak-cheung Chan, Deputy Director, Electrical and Mechanical Services Department, Hong Kong SAR Government, and Dr Rick Mo, Head of the Centre of Advanced Power and Autonomous Systems (APAS), Hong Kong Productivity Council, will share insights and discuss how the construction and transportation industries can build sustainable cities through effective collaboration.Other exciting activities include the FHKI Q-Mark Low Carbon Restaurant Award 2025 on 28 October, the first day of the Expo. The 6th Hydrogen Economy Forum will be held on the second day of the Expo, on 29 October. Diane Wong, JP, Under Secretary for Environment and Ecology, Hong Kong SAR Government will deliver the keynote address, while Dr Wang Ziyuan, Vice President, China Hydrogen Development and Innovation Alliance for Urban Gas will share insights on the opportunities and challenges of hydrogen energy in the Guangdong-Hong Kong-Macao Greater Bay Area. The Expo also features various seminars, including ‘Startup Edge’, which promotes the development of green start-ups, featuring presentations by start-up representatives from various environmental fields.On 31 October, Eco Expo will open to the public free of charge, to encourage public participation in environmental initiatives through a series of talks, workshops and activities. These include a seminar on the recent hot topic of extreme weather by Man Yee Chan, Chief Experimental Officer, Hong Kong Observatory, and a presentation by Ocean Park on Mission R, an initiative to protect endangered wildlife and their habitats. The public can also participate in various environmental workshops, and purchase eco-friendly products from the Green Mart.Other concurrent eventsThe Hong Kong International Outdoor and Tech Light Expo takes place from 28 to 31 October at AsiaWorld-Expo, showcasing outdoor and professional technical lighting solutions for commercial and industrial use; while the Hong Kong International Lighting Fair (Autumn Edition) opened yesterday and will run until 30 October at the Hong Kong Convention and Exhibition Centre. Free shuttle bus services are offered between these venues and other locations in the city throughout the fair period. Please refer to the following page for details:https://www.hktdc.com/event/ecoexpoasia/en/travel-to-fairground-awePhoto download: https://bit.ly/48MjH8FThe 20th Eco Expo Asia, jointly organised by the Hong Kong Trade Development Council (HKTDC) and Messe Frankfurt (HK) Ltd, opened at AsiaWorld-Expo today and runs until 31 October, attracting some 340 exhibitors. Yu Huiwen, Vice Minister of the Ministry of Ecology and Environment of the People's Republic of China, Ding Zhijun, Deputy Director of the Department of Energy Conservation and Comprehensive Utilization, Ministry of Industry and Information Technology of the People’s Republic of China; Tse Chin-wan, Secretary for Environment and Ecology of the Hong Kong SAR Government; Sophia Chong, HKTDC Executive Director, and other honourable guests attended the opening ceremonyYu Huiwen, Vice Minister of the Ministry of Ecology and Environment of the People's Republic of China (third left), Tse Chin-wan, Secretary for Environment and Ecology of the Hong Kong SAR Government (third right), Sophia Chong, HKTDC Executive Director (second left), and other honourable guests visited the ExpoThe Hong Kong SAR Government has invited government officials and representatives of quasi-governmental organisations from Belt and Road countries and regions, including Cambodia, Myanmar and Sri Lanka, to attend the 20th Eco Expo AsiaThis year’s Expo brings together 17 pavilions. For the first time, the Environmental Campaign Committee is hosting a pavilion, presenting 22 local green start-upsKorea is a new pavilion from overseas, with a strong lineupGreen and Smart Mobility is a new zone that has been added this year, focusing on green transport solutions and productsIndustry newcomers, such as research institutions and start-ups, bring innovative green solutionsThe Eco Asia Conference gathers global officials, industry leaders and experts to exchange insights on environmental issuesWebsiteEco Expo Asia: www.ecoexpoasia.comMedia enquiriesPlease contact the HKTDC’s Communications and Public Affairs Department:Stanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgClayton Lauw    Tel: (852) 2584 4472  Email: clayton.y.lauw@hktdc.orgThe HKTDC’s Media Room: http://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. About Messe FrankfurtThe Messe Frankfurt Group is one of the world’s leading trade fair, congress and event organisers with its own exhibition grounds. With a workforce of some 2,160 people at its headquarters in Frankfurt am Main and in 28 subsidiaries, it organises events around the world. Group sales in financial year 2022 were around €454 million. We serve our customers’ business interests efficiently within the framework of our Fairs & Events, Locations and Services business fields. One of Messe Frankfurt’s key strengths is its powerful and closely knit global sales network, which covers around 180 countries in all regions of the world. Our comprehensive range of services – both onsite and online – ensures that customers worldwide enjoy consistently high quality and flexibility when planning, organising and running their events. We are using our digital expertise to develop new business models. The wide range of services includes renting exhibition grounds, trade fair construction and marketing, personnel and food services. Sustainability is a central pillar of our corporate strategy. Here, we strike a healthy balance between ecological and economic interests, social responsibility and diversity.For more information, please visit our website at: www.messefrankfurt.com/sustainability. With its headquarters in Frankfurt am Main, the company is owned by the City of Frankfurt (60%) and the State of Hesse (40%). For more information, please visit our website at: www.messefrankfurt.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Rouyn-Noranda, Quebec--(ACN Newswire via SeaPRwire.com - October 28, 2025) - Radisson Mining Resources Inc. (TSXV: RDS) (OTCQX: RMRDF) ("Radisson" or the "Company") is pleased to announce assay results from fifteen new drill holes completed at its 100%-owned O'Brien Gold Project ("O'Brien" or the "Project") located in the Abitibi region of Québec. The fifteen holes represent step-outs below the existing geological model and the historic O'Brien Gold Mine and are part of an ongoing 140,000-metre drill program designed to test the overall scope of gold mineralization at the Project (see Radisson news release dated October 16, 2025). All holes intersected gold mineralization in characteristic quartz-sulphide-gold veins within alteration zones, and thirteen of the holes returned intercepts with grades and thicknesses consistent with the Project's existing mineral resources.Today's results include significant intercepts in three separate step-out locations (Figures 1 & 2), each of which has significance for the potential future growth of the Project's mineral resources. These are:Between Trends #1 and #2 at 1,000 Metres Vertical DepthOB-25-371W5 intersected 10.50 grams per tonne ("g/t") gold ("Au") over 6.5 metres, including 14.90 g/t Au over 1.5 metres and including 16.95 g/t Au over 1.0 metreOB-25-371W4 intersected 11.25 g/t Au over 2.5 metres, including 17.80 g/t Au over 1.5 metresOB-25-371W6 intersected 4.51 g/t Au over 9.0 metres, including 10.70 g/t Au over 1.5 metresBeneath the Historic "O'Brien Mine West" at 1,000 Metres Vertical Depth OB-25-376W1 intersected 9.16 g/t Au over 2.5 metres, including 14.70 g/t Au over 1.1 metresOB-25-376 intersected 8.05 g/t Au over 2.50 metres, including 15.75 g/t Au over 1.0 metreBeneath the Historic "O'Brien Mine" at 1,100 Metres Vertical DepthOB-24-337W11 intersected 7.00 g/t Au over 3.0 metres, including 12.60 g/t Au over 1.5 metres, and 13.00 g/t Au over 1.50 metresMatt Manson, President & CEO, commented: "Today's drill results illustrate the extension of classic, high-grade O'Brien gold mineralization across a broad front. We are reporting the first high-grade intercepts beneath the western portion of the historic mine, with drill hole OB-25-376W1 extending mineralization 160 metres below the former mine in this area. Drill hole OB-24-337W11 demonstrates continuity of high-grade mineralization below the main stope of the historic mine. Of particular note, drill holes OB-25-371W4 to W6 returned high-grade mineralization on the western edge of the deep extension of Trend #2, close to the observed extension of Trend #1 (Figures 1&2). This suggests that the apparent gap between these two trends is a function of drill coverage rather than geology, as we have suspected. Closing this gap with new drilling is a priority. With a fully-funded 140,000-metre drill program ongoing and an increase in rigs from the current four to an eventual eight, we are casting a wide net at O'Brien and seeing consistent success."Figure 1: Longitudinal Vertical Section and Plan View of Gold Vein Mineralization and Mineral Resources at the O'Brien Gold Project, with Today's Drill Holes IllustratedTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10977/272164_3fafb92ae4c30b1d_002full.jpgNotes on Calculation of Drill Intercepts:The O'Brien Gold Project Mineral Resource Estimate effective May 6, 2025 ("MRE") utilizes a 2.20 g/t Au bottom cut-off, a US$2,000 gold price, a minimum mining width of 1.2 metres, and a 40 g/t Au upper cap on composites. Intercepts presented in Table 1 are calculated with a 3.00 g/t Au bottom cut-off. True widths, based on depth of intercept and drill hole inclination, are estimated to be 30-80% of core length. Table 2 presents additional drill intercepts calculated with a 1.00 g/t bottom cut-off over a minimum 1.0 metre core length so as to illustrate the frequency and continuity of mineralized intervals within which high-grade gold veins at O'Brien are developed. Lithology Codes: PON-S3: Pontiac Sediments; V3-S, V3-N, V3-CEN: Basalt-South, North, Central; S1P, S3P: Conglomerate; POR-S, POR-N: Porphyry South, North; TX: Crystal Tuff; ZFLLC: Larder Lake-Cadillac Fault Zone.Figure 2: Longitudinal Vertical Section of Gold Vein Mineralization and Mineral Resources at the O'Brien Gold Project, with Deep Step-Out Drill Holes Completed and/or Published by the Company since December 2024. To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10977/272164_3fafb92ae4c30b1d_004full.jpgGold Mineralization at O'BrienGold mineralizing quartz-sulphide veins at O'Brien occur within a thin band of interlayered mafic volcanic rocks, conglomerates, and porphyritic andesitic sills of the Piché Group occurring in contact with the east-west oriented Larder Lake-Cadillac Break ("LLCB"). Gold, along with pyrite and arsenopyrite, is typically associated with shearing and a pervasive biotite alteration, and developed within multiple Piché Group lithologies and, occasionally, the hanging-wall Pontiac and footwall Cadillac meta-sedimentary rocks.As mapped at the historic O'Brien mine, and now replicated in the modern drilling, individual veins are generally narrow, ranging from several centimetres up to several metres in thickness. Multiple veins occur sub-parallel to each other, as well as sub-parallel to the Piché lithologies and the LLCB. Individual veins have well-established lateral continuity, with near-vertical, high-grade shoots developed over significant lengths. Based on the historic data available, it is clear that the former mine was "high-graded", with mining focussed on a main central stope and parallel veins identified but left undeveloped.The historic O'Brien mine produced over half a million ounces of gold from such veins and shoots at an average grade exceeding 15 g/t Au and over a vertical extent of at least 1,000 metres. Modern exploration has focussed on delineating well developed vein mineralization to the east of the historic mine, with additional high-grade shoots becoming evident in the exploration data over what has been described as a series of repeating trends ("Trend #s 0 to 5").Step-Out Drilling at O'BrienSince the end of 2024, Radisson has been pursuing a program of broad step-outs beneath the historic O'Brien Gold mine and the existing mineral resources designed to test the extent of mineralization at the Project. This drilling is accomplished with pilot holes followed by wedges and directional drilling to maximize drill efficiency. On October 16, 2025 Radisson announced the expansion of the step-out drill program to 140,000 metres employing an eventual eight drill rigs.The origin of the step-out drill program was the deep pilot hole OB-24-337, which was the first exploration drill hole located below the former mine workings since mining ended in 1957. This hole intersected 31.24 g/t Au over 8.0 metres, including 242.0 g/t Au over 1.0 metre at approximately 1,500 metres vertical depth (see Radisson news release dated December 16, 2024). With today's results, assay results from a total of 11 wedges from OB-24-337 have now been reported and up to six gold-bearing veins have been delineated over an area of approximately 250 metres (east-west) by 500 metres (vertical). Included in today's results is the eleventh wedge, OB24-337-W11, which intersected 7.00 g/t Au over 3.0 metres, including 12.60 g/t Au over 1.5 metres, and 13.00 g/t Au over 1.50 metres approximately 100 metres below the final historic mining stope (Figure 1). This serves to demonstrate the continuity of mineralization from the former mine downwards towards the cluster previously published wedges (Figures 1 & 2; see Radisson news release dated July 16, 2025). Current drilling in this area is focussed on infilling with pilot holes and wedge extensions both above and below the OB-24-337 pattern of wedge branches to test the full continuity of mineralization from the historic mine down to 2 kilometres depth.Step-out drilling with wedge branches has also confirmed high-grade mineralization 170 metres below the base of the existing mineral resources at Trend #1 and 300 metres at Trend #2. These have included pilot hole OB-24-324, which intersected 27.61 g/t Au over 6.0 metres at Trend #1 (see Radisson news release dated October 30, 2024) and OB-24-363, which intersected 8.41 g/t Au over 2.20 metres, including 14.40 g/t Au over 1.20 metres and 9.07 g/t Au over 1.80 metres, including 12.10 g/t Au over 0.90 metres at Trend #2 (see Radisson news release dated September 8, 2025). Today's results include six wedges from drill hole OB-25-371, which demonstrate strongly developed, high-grade mineralization on the western edge of the deep extension of Trend #2. These holes include OB-25-371W5, which intersected 10.50 g/t Au over 6.5 metres, including 14.90 g/t Au over 1.5 metres and including 16.95 g/t Au over 1.0 metre (Figures 1&3). The significance of these holes is that the apparent separation of Trend #1 and Trend #2 is based, in part, on a data gap caused by drill rig access restrictions and a lack of drilling (Figure 2). Targeting this gap and testing for continuity of mineralization between Trends #1 and #2, as well as at depth, is a priority of the current drill program.Today's results also include the first drill holes located below the western portion of the historic O'Brien Gold Mine, designated "O'Brien Mine West". As with the main mining area, no exploration had been conducted below O'Brien Mine West since operations ended in 1957. From pilot hole OB-25-376 and wedge branches W1 to W5, five holes returned intercepts with grades and thicknesses consistent with the Project's mineral resources, including OB-25-376W1, which intersected 9.16 g/t Au over 2.5 metres, including 14.70 g/t Au over 1.1 metres (Figure 1). This now extends gold mineralization at O'Brien Mine West 160 metres below the base of the former mine workings (Figure 4).Figure 3: Vertical Cross Section through "Trend #2" with Drill Hole Wedges OB-25-371W2 to W6To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10977/272164_3fafb92ae4c30b1d_005full.jpg Figure 4: Vertical Cross Section through "O'Brien Mine West" with Drill Hole OB-25-376 and Wedges W1 to W5To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10977/272164_3fafb92ae4c30b1d_006full.jpgQA/QCAll drill cores in this campaign are NQ in size. Assays were completed on sawn half-cores, with the second half kept for future reference. The samples were analyzed using standard fire assay procedures with Atomic Absorption (AA) finish at ALS Laboratory Ltd, in Val-d'Or, Quebec. Samples yielding a grade higher than 10 g/t Au were analyzed a second time by fire assay with gravimetric finish at the same laboratory. Mineralized zones containing visible gold were analyzed with metallic sieve procedure. Standard reference materials, blank samples and duplicates were inserted prior to shipment for quality assurance and quality control (QA/QC) program.Qualified Persons Disclosure of a scientific or technical nature in this news release was prepared under the supervision of Mr. Richard Nieminen, P.Geo, (QC), a geological consultant for Radisson and a Qualified Person for purposes of NI 43-101. Mr. Luke Evans, M.Sc., P.Eng., ing, of SLR Consulting (Canada) Ltd., is the Qualified Person responsible for the preparation of the MRE at O'Brien. Each of Mr. Nieminen and Mr. Evans is independent of Radisson and the O'Brien Gold Project.About Radisson MiningRadisson is a gold exploration company focused on its 100% owned O'Brien Gold Project, located in the Bousquet-Cadillac mining camp along the world-renowned Larder-Lake-Cadillac Break in Abitibi, Québec. A July 2025 Preliminary Economic Assessment described a low cost and high value project with an 11-year mine life and significant upside potential based on the use of existing regional infrastructure. Indicated Mineral Resources are estimated at 0.58 million ounces (2.20 million tonnes at 8.2 g/t Au), with additional Inferred Mineral Resources estimated at 0.93 million ounces (6.67 million tonnes at 4.4 g/t Au). Please see the NI 43-101 "O'Brien Gold Project Technical Report and Preliminary Economic Assessment, Québec, Canada" effective June 27, 2025, and other filings made with Canadian securities regulatory authorities available at www.sedarplus.ca for further details and assumptions relating to the O'Brien Gold Project. For more information on Radisson, visit our website at www.radissonmining.com or contact:Matt MansonPresident and CEO416.618.5885mmanson@radissonmining.comKristina PillonManager, Investor Relations604.908.1695kpillon@radissonmining.comForward-Looking StatementsThis news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections, and interpretations as at the date of this news release. Forward-looking statements including, but are not limited to, statements with respect to the ability to execute the Company's plans relating to the O'Brien Gold Project as set out in the Preliminary Economic Assessment; the Company's ability to complete its planned exploration and development programs; the absence of adverse conditions at the O'Brien Gold Project; the absence of unforeseen operational delays; the absence of material delays in obtaining necessary permits; the price of gold remaining at levels that render the O'Brien Gold Project profitable; the Company's ability to continue raising necessary capital to finance its operations; the ability to realize on the mineral resource and mineral reserve estimates; assumptions regarding present and future business strategies; local and global geopolitical and economic conditions and the environment in which the Company operates and will operate in the future; planned and ongoing drilling; the significance of drill results; the ability to continue drilling; the impact of drilling on the definition of any resource; and the ability to incorporate new drilling in an updated technical report and resource modelling; the Company's ability to grow the O'Brien Gold Project; and the ability to convert inferred mineral resources to indicated mineral resources. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "interpreted", "management's view", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. Except for statements of historical fact relating to the Company, certain information contained herein constitutes forward-looking statements Forward-looking information is based on estimates of management of the Company, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others; the risk that the O'Brien Gold Project will never reach the production stage (including due to a lack of financing); the Company's capital requirements and access to funding; changes in legislation, regulations and accounting standards to which the Company is subject, including environmental, health and safety standards, and the impact of such legislation, regulations and standards on the Company's activities; price volatility and availability of commodities; instability in the global financial system; the effects of high inflation, such as higher commodity prices; the risk of any future litigation against the Company; changes in project parameters and/or economic assessments as plans continue to be refined; the risk that actual costs may exceed estimated costs; geological, mining and exploration technical problems; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the mining industry; delays in obtaining governmental approvals or financing; risks relating to the drill results at O'Brien; the significance of drill results; and the ability of drill results to accurately predict mineralization. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither the Company nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. The Company believes that this forward-looking information is based on reasonable assumptions, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this press release should not be unduly relied upon. The Company does not undertake, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law. These statements speak only as of the date of this news release.Please refer to the "Risks and Uncertainties Related to Exploration" and the "Risks Related to Financing and Development" sections of the Company's Management's Discussion and Analysis dated April 29, 2025 for the year ended December 31, 2024, and the Company's Management's Discussion and Analysis dated August 27, 2025 for the three-month period ended June 30, 2025, all of which are available electronically on SEDAR+ at www.sedarplus.ca. All forward-looking statements contained in this press release are expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272164 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2025年10月27日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（「康哲藥業」）欣然宣佈，於2025年10月27日，康哲藥業通過子公司CMS VISION INTERNATIONAL MANAGEMENT LIMITED與Novartis Pharma Services AG （「諾華」）就雷珠單抗注射液（「諾適得(R)」）、布西珠單抗注射液（「倍優適(R)」）簽訂經銷協議（「協議」）。根據協議，康哲藥業獲得產品在中華人民共和國（為協議之目的，不含香港特別行政區、澳門特別行政區、台灣）的協議所約定之獨家進口、經銷、銷售、推廣權利；諾華繼續負責生產、供應產品。合作期限為協議約定的生效日起五年。兩款合作產品均已在中國獲批上市，其中諾適得(R)是中國首個獲批用於眼科的抗血管內皮生長因子（VEGF）藥物，具備成熟的臨床應用經驗，為眾多眼底疾病患者提供了可靠保障；諾適得(R)已被批准用於治療濕性年齡相關性黃斑變性（nAMD）、糖尿病性黃斑水腫(DME)、視網膜靜脈阻塞(RVO)繼發的黃斑水腫等多項眼底新生血管性疾病。另一款產品倍優適(R)為新一代抗VEGF藥物，2025年5月中國獲批用於DME，其憑藉獨特的超小分子（僅26kDa）、高濃度創新優勢，顯著改善視網膜解剖學結構，助力更多DME患者獲得視力改善，減輕治療負擔。康哲藥業眼科業務公司「康哲維盛」專注於在全球範圍內佈局、開發臨床急需的眼科藥械創新產品，致力於打造「中國眼科醫藥龍頭」，此次合作將提升康哲維盛在眼科領域的整體競爭力。康哲維盛已覆蓋眼底疾病、視疲勞、青光眼等眼科疾病領域，諾適得(R)及倍優適(R)加入後，將與在售獨家藥施圖倫滴眼液（七葉洋地黃雙苷滴眼液）、在售獨家醫療器械EyeOP1青光眼治療儀在客戶、專家資源、渠道網絡上產生高度協同，提升康哲維盛在眼科領域的學術品牌競爭力，為持續合作、開發臨床急需的眼科創新產品帶來正向推動作用，為眼科疾病患者提供更多元化的治療選擇。同時康哲維盛專業的眼科團隊將整合市場渠道與學術資源，提升團隊整體效能，並預期對康哲藥業業績產生積極正面影響。關於諾適得(R)及眼底新生血管性疾病的更多信息諾適得(R)是重組抗VEGF人源化單克隆抗體Fab片段，靶向抑制人血管內皮生長因子A（VEGF-A），以抑制血管內皮細胞增殖、新生血管生成和血管滲漏。諾適得(R)作為中國首個獲批用於眼科的抗VEGF藥物[3]，自2011年在中國上市以來，已被批准用於治療多項眼底新生血管性疾病，包括nAMD、DME、RVO繼發的黃斑水腫、脈絡膜新生血管(CNV)、糖尿病視網膜病變（DR）、早產兒視網膜病變(ROP)。諾適得(R)已於2017年被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》，具備成熟的臨床應用經驗，為眾多眼底疾病患者提供了可靠保障。眼底新生血管性疾病是一類以血管通透性增加、血管滲漏以及血管完整性的缺失為特徵的嚴重致盲性眼病，主要包括nAMD、DR、DME、RVO、CNV、ROP等。抗VEGF藥物是多個權威指南推薦治療眼底新生血管性疾病的一線療法[3, 4]。根據弗若斯特沙利文報告，中國眼底新生血管性疾病患者預計將從2019年的47.8百萬人增至2030年的61.2百萬人。中國抗VEGF眼科藥物市場預期將從2019年的24億元增長至2030年的186億元。根據《抗VEGF藥物治療眼底新生血管性疾病》，諾適得(R)作為中國首個獲批用於治療眼底新生血管性疾病的抗VEGF藥物，在多項臨床試驗中均顯示出良好的安全性和有效性，已被廣泛應用於治療眼底新生血管性疾病，它的問世代表了眼科臨床治療的一個重大進步[5]。關於倍優適(R)及DME適應症的更多信息倍優適(R)是一種靶向VEGF-A的新型人源化單鏈抗體片段，已於2025年5月獲得中國國家藥品監督管理局批准用於DME。作為目前分子量最小的抗VEGF藥物（僅26kDa），倍優適(R)治療DME負荷期每6周給藥一次（其他抗VEGF藥物負荷期每4周給藥1次），維持期每2至3個月給藥一次。倍優適(R)針對初治DME患者的全球3期KESTREL和KITE研究均達到主要療效終點且視力獲益持續至100周。倍優適(R)6mg組患者IRF（視網膜內積液）和/或SRF（視網膜下積液）更少。倍優適(R)首年中位注射次數（7次）少於阿柏西普（9次），同時總體安全性與後者相當[6]。中國真實世界研究BEST研究顯示，經治不達標的DME患者經倍優適(R)首針治療1周後BCVA即較基線提升6.1字母，注射第3針（12周）提升10字母，倍優適(R)為經治DME提供更優化的治療選擇[7]。DME是由於黃斑區毛細血管滲漏所致的視網膜增厚，是血視網膜屏障破壞的結果，主要影響中心視力[8]。據弗若斯特沙利文報告，2025年中國約有7.89百萬例DME患者。但即使按目前規範的抗VEGF藥物治療方案，仍有約30%-50%DME患者積液控制不佳[9-11]。《2022中國常見眼底病慢病管理現狀白皮書》調研顯示，我國患者治療依從性較差，30%以上DME患者未能完成負荷期治療。臨床亟需更強效、更持久、依從性更高的治療藥物以改善DME患者的診療現狀。新一代抗VEGF藥物倍優適(R)為解決這一難題提供了潛在方法，其憑藉獨特的超小分子、高濃度創新優勢，顯著改善視網膜解剖學結構，助力更多DME患者獲得視力改善，減輕治療負擔。關於諾華諾華是一家全球知名的醫藥企業，總部位於瑞士巴塞爾。諾華聚焦患者需求緊迫的四大核心治療領域（心血管、腎臟及代謝，腫瘤，免疫，神經科學）以及五大關鍵技術平台（化學療法、生物療法、xRNA療法、放射配體療法、基因和細胞療法）。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平台型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。參考文獻/資料1. 產品相關信息可在諾華官網查詢，網址：https://www.novartis.com.cn/news/big-news-noxtex-welcomes-the-approval-of-dual-indications2. Lim, Jennifer I et al. “Diabetic Retinopathy Preferred Practice Pattern(R).” Ophthalmology vol. 132,4 (2025): P75-P162. doi:10.1016/j.ophtha.2024.12.0203. 中華醫學會眼科學分會眼底病學組,中國醫師協會眼科醫師分會眼底病學組.中國年齡相關性黃斑變性臨床診療指南(2023年)[J].中華眼科雜誌,2023,59(5):347-366.4. 許迅,王建影.疾病譜變化驅動臨床藥物更迭[N].健康報,2023-07-05(005).5. 侯慧敏,常雪柯,靳雨佳,等.抗VEGF藥物治療眼底新生血管性疾病[J].國際眼科縱覽,2024,48(6):464-470.6. Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diaßbetic Macular Edema. Am J Ophthalmol. 2024;260:70-83.7. 餘洪華，2025中國眼底病論壇暨國際視網膜研討會，6月4日-7日，中國無錫8. 中華醫學會眼科學分會眼底病學組,中國醫師協會眼科醫師分會眼底病學組. 我國糖尿病視網膜病變臨床診療指南(2022年)[J]. 中華眼底病雜誌,2023,39(2):99-124.9. 戴虹, 盧穎毅. 糖尿病黃斑水腫治療策略的變化與面臨的問題[J].中華眼底病雜誌, 2022, 38(1): 6-9.10. Bressler, Neil M et al. “Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.” JAMA ophthalmology vol. 136,3 (2018): 257-269.11. Chatziralli, I et al. “Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.” Eye (London, England) vol. 31,11 (2017): 1594-1599.康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月28日 - (亞太商訊 via SeaPRwire.com) - 2025年10月28日，權威管理諮詢機構久謙諮詢發佈全球全景及運動相機市場研究報告。報告指出，近年全球運動相機與全景相機市場份額出現顯著變化，市場格局正經歷快速重構。在運動相機領域，曾經佔據全球主導地位的是美國品牌GoPro，2022-23年，GoPro依靠HERO系列穩居頭部，全球市場佔有率75%以上，但到2025年其收入佔全球市場份額已逐步收縮至18%。而經過三年，市場迎來"新王"——大疆憑藉多年戰略佈局、產品節奏及生態協同，快速崛起，到2025年Q3大疆在這個領域的收入佔全球市場份額已達66%，以絕對優勢成為全球運動相機市場第一。另一中國品牌影石目前則佔據約13%的市場份額。 全景相機的市場格局也迎來激烈變動。大疆於今年7月31日入局該領域，在不到三個月的時間內，其首款全景相機Osmo360，憑藉跨端應用與高性價比的優勢，分別在中國電商渠道獲得了49%的市場份額，全球市場份額達43%。加速推動全球全景相機市場格局重構。最近京東"運動相機金榜"出爐，也見證了整個運動相機賽道，已經徹底進入"大疆時間"。大疆Osmo Action 5 Pro、大疆Osmo Nano、大疆Osmo Action 4三款產品直接包攬運動相機金榜前三。從更詳細的市場表現上看，在京東"戶外全景運動相機熱賣榜"中，大疆Osmo 360發佈接近不到3個月也奪得榜首，且已經在此領域上佔據了49天的位置。大疆在運動相機和全景相機的市佔和銷量數據，不僅是中國品牌科技硬實力的證明，也顯示大疆在原來佔據絕對優勢的無人機行業之外，以持續成長的影像技術矩陣及生態佈局，在全球手持影像市場也取得了絕對優勢領跑的地位。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月28日 - (亞太商訊 via SeaPRwire.com) - 2025年，整個冰激淩行業普遍處於謹慎和觀望的狀態，面對消費者需求的不斷變化，各家都在努力探索新的打法和方向。在這種充滿挑戰的局面下，作為行業領導者的蒙牛，卻率先找到了破局之道。上半年，憑藉一系列亮眼的產品和營銷創新，蒙牛的冰品業務交出了同比增長15%的優異答卷。這一增速，顯著超越了行業平均水平。考慮到七八月份，全國各地持續高溫，冰品消費熱度不減，市場對於蒙牛冰品在三季度乃至全年的業績增長也更添了幾分樂觀與期待。在現制茶飲跨界打劫、渠道日益碎片化的複雜局面下，一個深耕冰淇淋市場多年的傳統巨頭，為何能重拾增長動力，實現如此強勁的逆勢上揚？這背後，隱藏著一套怎樣的增長秘訣？ 經典為本+爆款不斷在快速消費品領域，一切商業邏輯的起點和終點，終究是產品本身。面對消費者需求的高度分化與迅速變換，蒙牛祭出了一套清晰而有力的組合拳，即所謂的「守正出奇」。所謂「守正」，是穩固基本盤。蒙牛將大量的核心資源聚焦於「隨變」與「綠色心情」兩大國民品牌，通過對經典大單品的持續優化，不斷夯實市場份額。數據顯示，整個上半年，兩大品牌的合計銷售佔比已穩步提升至55.2%，成為整個冰品業務最穩固的壓艙石，也奠定了全年業績增長的穩定基礎。而「出奇」，則是通過持續不斷地推出爆款新品，來製造新的增長勢能，點燃消費者對品牌的關注與熱情。如果說經典產品是蒙牛冰品這艘巨輪的船身，那麼爆款新品就是驅動它破浪前行的強大引擎。2025年上半年，蒙牛新上市了多款高品質、高質價比、高情緒價值的新品：無論是融合了經典懷舊造型的「隨變轉」，還是色彩繽紛、顏值出眾的「絢彩冰系列」，亦或是開闢了全新食用場景的「冰杯」，都成為了現象級的爆款，而一系列的奶冰產品更是備受消費者的青睞，新推出的鮮牛奶冰激淩系列、高端生牛乳冰激淩及活菌酸奶冰激淩，滿足了消費者對健康天然原料與美味的雙重需求。據統計，上半年共有9支新品強勢突破了千萬級銷量的門檻，新品整體銷售額佔比同比提升了2.7個百分點，創下歷史新高。除此之外，二三季度，蒙牛在杯裝產品上的持續發力，也讓線上線下的銷售熱度進一步攀升。這種「守正」與「出奇」的結合，展現出了一家老牌企業應有的戰略智慧：既有經典產品帶來的品牌信任與渠道忠誠度，又有爆款新品帶來的市場話題與增量用戶，二者共同構成了一個攻守兼備、富有韌性的產品矩陣組合。新興渠道與傳統渠道和諧共舞如果說產品是決定核心價值的1，那麼渠道就是1後面跟著的那一連串的0。面對近幾年線上流量持續分化、線下賣場客流下滑的嚴峻挑戰，蒙牛冰品的渠道策略完成了一次極為華麗的轉身——從過去的「廣度覆蓋」轉向了今年的全渠道全場景「深度運營」，而成功的關鍵，則是以一套多元化的產品組合，去精准適配不同渠道的用戶需求特點。這不再是簡單的「鋪貨」，而是一場新興渠道與傳統渠道協作共生的「雙人舞」。線上線下的新興渠道，已然成為業務增長最強勁的引擎。2025年上半年，新興渠道整體銷量猛增33%，其中生鮮電商的銷售增速更是超過40%，豆冰、水冰等品類全面超越競對，直營閃電倉的客單價實現了爆發性增長。這一系列的成績，證明了蒙牛對線上消費趨勢的敏銳捕捉和高效執行。而針對新興渠道的消費特點，蒙牛展現出了極強的策略適配能力。例如，今年借勢美團517吃貨節，蒙牛通過趣味內容植入美團外賣小哥形象，將媒介流量精准導向美團的銷售渠道，並聯動頭部便利店進行直播，實現了營銷動作與渠道銷售的無縫銜接，高效地放大了銷售效果。在傳統渠道，蒙牛同樣展現了強大的調整和適應能力。面對傳統商超賣場的人流量下滑，公司並未消極應對，而是主動出擊，將重心聚焦於校園、社區等高產出門店，通過提升冰櫃規模與專櫃管控，實現了大盤的穩定增長。在這個過程當中，蒙牛還通過引入一系列的數智化手段，成功的強化了對銷售終端的掌控力、優化了渠道的履約能力和運營效率。同時，為了尋找新的增長點，蒙牛大力開拓新賽道，積極發展會員店、零食量販店等新興零售業態，通過專供、聯名等模式打造渠道大單品，成功對沖了傳統商超渠道的流量挑戰。在定制業務方面，蒙牛的滲透同樣不遺餘力。通過積極拓展餐飲連鎖、熱門景區、交通樞紐等場景的覆蓋，產品得以觸達消費者生活的更多細微觸點，成功打造了多款基於不同場景的定制化產品，開拓銷售新增長點。除此之外，蒙牛的目光還投向了消費潛力更加廣闊的港澳台及海外市場。旗下高端品牌蒂蘭聖雪成功入駐香港市場，成為中國大陸首個獲批香港食環署牌照的冰淇淋品牌。這不僅是品質的證明，更是品牌破圈和高端佔位的一次關鍵落子。營銷的本質是情感共鳴在Z世代成為消費主力的今天，單純的功能性滿足，已經不足以贏得年輕人的青睞，能夠與消費者建立並維持長期的情感共鳴，才是一個消費類品牌真正的護城河。有鑑於此，蒙牛的營銷思路，已經逐漸超越了傳統的廣告投放，進化為「產品+內容+媒介+渠道」四位一體的高度整合，其最終目標，是要與年輕一代消費者建立深度、可持續的情感鏈接。為了實現這一目標，與國民級IP的聯名，就成為引爆新品勢能的快捷方式。「綠色心情紅豆雙皮奶」與國民熱劇《甄嬛傳》的聯動，以「一口紅豆雙皮奶，穿越到宮廷」的巧妙構思，迅速捕獲了年輕人的心，在直播首銷期就取得了非常好的銷售成績和話題熱度。而更深層次的打法，則是以場景驅動增長。蒙牛的營銷團隊一改過去的做法，不再被動地等待消費者的關注，而是主動地去創造和融入年輕人的生活場景，通過全年覆蓋11座城市的音樂節現場，將蒙牛品牌與潮流、自由的文化符號深度綁定，在年輕人當中了取得非常好的口碑和促銷效果，尤其是「把音樂節開去超市」的創意活動，更是在五四青年節期間沖上熱搜，成為微博熱門話題。在這一系列操作的背後，貫穿始終的是蒙牛對品牌年輕化戰略的堅定執行。通過一次次成功的破圈營銷，蒙牛不斷刷新著品牌在Z世代心中的形象。對於新一代的消費者，蒙牛不再僅僅是一個耳熟能詳的食品製造商，更是一個活躍在年輕人文化場景中的「玩伴」，是一個可以分享樂趣、有共同語言的夥伴。這樣的情感鏈接強度，已經遠遠超出了狹義的產品營銷範疇，而是成為新時代品效合一營銷思想的經典案例。整個二、三季度，蒙牛在線上的話題熱度和傳播效應，始終保持了極高的水平，也是對這一全新營銷思路的一次成功驗證。可持續的增長飛輪所有成功的戰略，最終都要回歸到財務數據的驗證。蒙牛冰品業務的價值，不僅在於當下令人矚目的高增長，更在於其增長邏輯的可持續性。從業績上看，上半年15%的同比增長，顯著跑贏了行業大盤，展示出了強大的增長潛力。更值得注意的是，冰品業務佔蒙牛總收入的比重從去年同期的7.5%提升至9.3%，對集團整體業績的貢獻度顯著增強，其戰略地位日益凸顯。從可持續性來看，當前的成績並非源於短期的市場刺激或單一的爆款效應，而是產品力、渠道力、營銷力三大戰略協同發力的必然結果。一個穩固的經典產品基本盤，一套能夠精准適配多元渠道的運營體系，一種能與新一代消費者同頻共振的品牌溝通能力，這三大支柱共同構建了蒙牛冰品業務面向未來的、可持續的增長飛輪。在消費者需求變化迅速、市場環境充滿挑戰的當下，蒙牛冰淇淋的逆勢增長，無疑為整個消費品行業提供了一個寶貴的範本：對於傳統快消領域的巨頭而言，只要能夠與時俱進，在產品、渠道、營銷等多個層面不斷自我革新，就依然能夠穿越週期，在龐大的現有基數之上，開啟更加令人期待的二次增長曲線。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - The International Leo Tolstoy Peace Prize Jury announced the 2025 laureates in recognition of outstanding efforts contributing to regional harmony and security in Central Asia. The award honors the signing of the Treaty on the Junction Point of State Borders and the Khujand Declaration of Eternal Friendship in Khujand, Tajikistan, on March 31, 2025 — landmark agreements that strengthen legal frameworks for mutual trust and cross-border collaboration.Established on June 22, 2022, by the Russian Historical Society, the Russian Peace Foundation, and the Russian Military Historical Society, the International Leo Tolstoy Peace Prize Foundation convenes juries including prominent figures from Argentina, Belarus, India, China, Russia, France, South Africa, and Japan. Jury Chairman Valery Gergiev, renowned conductor and artistic director of the Mariinsky Theatre, emphasized the prize’s mission to “advance global understanding and mutual respect.” He noted the growing reach of the peace movement inspired by Russian writer-philosopher Leo Tolstoy, expressing hope that the prize could, like music, “help nations listen and truly hear one another.”The 2025 honor celebrates the joint efforts of:- Sadyr Japarov, Kyrgyz Republic- Emomali Rahmon, Republic of Tajikistan- Shavkat Mirziyoyev, Republic of UzbekistanTheir collaboration has strengthened stability, sustainable growth, and the international profile of Central Asia. The award ceremony date will be announced soon.About the PrizeThe International Leo Tolstoy Peace Prize is awarded by an international jury established by the founders of the L.N. Tolstoy International Peace Prize Foundation. The jury is composed of distinguished Russian and foreign figures of recognized international standing and moral authority.Candidates for the Prize may include individuals, initiative groups, national and international public foundations, organizations, movements, scientific and research centers, as well as educational institutions. Self-nomination is not permitted; however, nominators are encouraged to publicly discuss the candidates they propose. Rooted in the humanist ideals of Leo Tolstoy, the Prize honors those whose work embodies the pursuit of peace, moral integrity, and shared progress for humanity.Media contactOrganization: The International Leo Tolstoy Peace PrizeContact: Media teamWebsite: https://tolstoypeaceprize.org Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 27 October 2025, the Group through its subsidiary CMS VISION INTERNATIONAL MANAGEMENT LIMITED entered into a Distribution Agreement (the “Agreement”) with Novartis Pharma Services AG (“Novartis”) for Ranibizumab Injection (“Lucentis®”) and Brolucizumab Injection (“Beovu®”). In accordance with the Agreement, the Group has obtained the exclusive right to import, distribute, sell and promote as specifically agreed upon in the Agreement in the People’s Republic of China (for the purpose of the Agreement, excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan) ; Novartis will continue to be responsible for the production and supply of the products. The term of cooperation comes into effect on the effective date of the Agreement and remains valid for a period of five years.Both collaborative products have been approved for marketing in China. Among them, Lucentis® is the first anti-vascular endothelial growth factor (VEGF) drug approved for ophthalmic use in China, and has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases. Lucentis® has been approved for the treatment of multiple ocular neovascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), etc. Another product, Beovu®, is a next-generation anti-VEGF drug approved in China in May 2025 for the treatment of DME. Leveraging its innovative advantages of ultra-small molecular weight (only 26 kDa) and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.The Group’s ophthalmology business company, “CMS Vision”, focuses on deploying and developing innovative ophthalmic pharmaceuticals and medical devices with urgent clinical needs on a global scale, striving to become a “leading ophthalmology pharmaceutical company in China”. This collaboration will enhance the overall competitiveness of CMS Vision in the field of ophthalmology. CMS Vision already covers ophthalmic disease areas such as fundus diseases, asthenopia and glaucoma. With the addition of Lucentis® and Beovu®, the portfolio will generate strong synergies with the marketed exclusive drug Augentropfen Stulln Mono Eye Drops (Esculin and Digitalisglycosides Eye Drops) and the marketed exclusive medical device EyeOP1 Glaucoma Treatment Device in terms of customer base, expert resources, and channel networks. This will further strengthen CMS Vision’s academic brand competitiveness in ophthalmology, provide positive momentum for sustained collaboration and the development of clinically needed innovative ophthalmic products, and offer patients more diverse treatment options. At the same time, CMS Vision’s professional ophthalmology team will integrate marketing channels and academic resources to improve the overall team efficiency. The collaboration is expected to have a positive impact on the Group’s financial results.More Information about LUCENTIS® and Ocular Neovascular DiseasesLucentis® is a recombinant humanized monoclonal antibody Fab fragment targeting VEGF. It targets and inhibits human vascular endothelial growth factor A (VEGF-A), thereby suppressing vascular endothelial cell proliferation, neovascularization, and vascular leakage. As the first anti-VEGF drug approved for ophthalmic use in China[3], Lucentis® has been approved for the treatment of multiple ocular neovascular diseases since its launch in China in 2011, including nAMD, DME, macular edema following RVO, choroidal neovascularization (CNV), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). In 2017, Lucentis® was included in the National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance. It has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases.Ocular neovascular diseases are a group of severe blinding ophthalmic conditions characterized by increased vascular permeability, vascular leakage, and loss of vascular integrity, mainly including nAMD, DR, DME, RVO, CNV, ROP, etc. Anti-VEGF drugs are recommended as first-line therapy for ocular neovascular diseases in multiple authoritative guidelines[3, 4]. According to a Frost & Sullivan report, the number of patients with ocular neovascular diseases in China is projected to increase from 47.8 million in 2019 to 61.2 million in 2030. The Chinese ophthalmic anti-VEGF drug market is expected to grow from RMB 2.4 billion in 2019 to RMB 18.6 billion in 2030. As stated in Anti-VEGF Drugs for Fundus Neovascular Diseases, Lucentis®—the first anti-VEGF drug approved for the treatment of ocular neovascular diseases in China—has demonstrated favorable safety and efficacy in multiple clinical trials. It has been widely used in the treatment of ocular neovascular diseases, and its launch represents a major advancement in clinical ophthalmic treatment[5].More Information about BEOVU® and the DME IndicationBeovu® is a novel VEGF-A-targeted humanized single-chain antibody fragment. It received approval from the National Medical Products Administration of China (NMPA) in May 2025 for the treatment of DME. As the current anti-VEGF drug with the smallest molecular weight (only 26 kDa), Beovu® is administered once every 6 weeks during the loading phase of the DME treatment (compared to once every 4 weeks for other anti-VEGF drugs) and once every two to three months during the maintenance phase. In the global Phase 3 KESTREL and KITE Studies for treatment-naive DME patients, Beovu® met all primary efficacy endpoints and the visual benefit persisted until Week 100. Additionally, patients in the Beovu® 6mg group had less intraretinal fluid (IRF) and/or subretinal fluid (SRF). The median number of injections of Beovu® in the first year (7 times) was lower than that of aflibercept (9 times), while its overall safety profile was comparable to the latter[6]. Data from the Chinese real-world study (BEST Study) showed that for previously treated and inadequately controlled DME patients, BCVA improved by 6.1 letters from baseline 1 week after the first injection of Beovu®, and by 10 letters after the third injection (Week 12). Beovu® provides a more optimized treatment option for previously treated DME patients[7].DME is a retinal thickening caused by capillary leakage in the macular area, which is the result of the breakdown of the blood retinal barrier and mainly affects central vision.[8]. According to a Frost & Sullivan report, there are approximately 7.89 million DME patients in China in 2025. However, even with the current standard anti-VEGF regimens, approximately 30%-50% of DME patients still exhibit suboptimal fluid control[9-11]. A survey in the 2022 White Paper on the Current Status of Chronic Disease Management for Common Ocular Fundus Diseases in China showed that treatment adherence among Chinese patients is relatively poor, with over 30% of DME patients failing to complete the loading phase treatment. There is an urgent clinical need for more potent, longer-lasting, and more adherence-friendly treatment options to improve the diagnosis and treatment of DME patients. As a next-generation anti-VEGF drug, Beovu® offers a potential solution to this challenge. Leveraging its innovative advantages of ultra-small molecular weight and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.About NOVARTISNovartis is a globally renowned pharmaceutical company headquartered in Basel, Switzerland. The company focuses on four core therapeutic areas with urgent patient needs—Cardiovascular, Renal and Metabolic Disease, Oncology, Immunology, and Neuroscience—as well as five key technology platforms: Chemotherapy, Biotherapy, xRNA, Radioligand Therapy, and Gene and Cell Therapy.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. Product-related information can be found on the Novartis website at:https://www.novartis.com.cn/news/big-news-noxtex-welcomes-the-approval-of-dual-indications 2. Lim, Jennifer I et al. “Diabetic Retinopathy Preferred Practice Pattern®.” Ophthalmology vol. 132,4 (2025): P75-P162. doi:10.1016/j.ophtha.2024.12.0203. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of age-related macular degeneration in China(2023)[J]. Chinese Journal of Ophthalmology,2023,59(5):347-366. 4. Xu Xun, Wang Jianying. Changes in Disease Spectrum Drive the Evolution of Clinical Medications [N]. Health News, 2023-07-05(005).5. Hou Huimin, et al. Anti-VEGF drugs for fundus neovascular diseases[J].International Review of Ophthalmology,2024,48(6):464-470.6. Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol. 2024;260:70-83.7. Honghua Yu, 2025 China Forum on Fundus Diseases & International Retina Symposium, June 4-7, Wuxi, China.8. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chinese Journal of Ocular Fundus Diseases,2023,39(2):99-124.9. Dai Hong, et al. Advances in the treatment strategies of diabetic macular edema and the problems[J]. Chinese Journal of Ocular Fundus Diseases,2022, 38(1): 6-9.10. Bressler, Neil M et al. “Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.” JAMA ophthalmology vol. 136,3 (2018): 257-269.11. Chatziralli, I et al. “Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.” Eye (London, England) vol. 31,11 (2017): 1594-1599.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

馬薩諸塞州特克斯伯里, 2025年10月27日 - (亞太商訊 via SeaPRwire.com) - CIL 的全球製造網絡遍佈北美、歐洲與亞洲，使公司能為製藥合作夥伴提供多元且具韌性的供應鏈。每一項 ISOAPI-D 產品皆於通過 ISO 9001 認證的設施中製造，確保在整個生產流程中達到最高的品質標準、法規遵循與完整的可追溯性。ISOAPI-DISOAPI-D Power of Deuterium: Smarter, Stronger TherapeuticsISOAPI-D 系列的核心組成之一為重水（D₂O），該原料僅由經核准的供應商提供。此產品具完整追溯性且不含氚（tritium），符合製藥產業嚴格的安全與法規要求。ISOAPI-D 系列同樣包含先進的中間體，可使合成途徑更加簡化。透過減少合成步驟並優化生產效率，這些中間體有助於降低製造成本，並加速新療法的上市進程。自 1981 年以來，CIL 一直是全球領先製藥與生物技術公司的優質去氘材料可信賴供應商。隨著 ISOAPI-D 的推出，CIL 將這份對品質與可靠性的長期承諾持續延伸，為客戶提供安全、高品質的關鍵試劑供應，並在研發流程中降低營運風險。CIL 去氘試劑應用業務開發經理 Tasha Agreste 表示：「ISOAPI-D 代表了我們持續推動製藥創新的下一步。我們擴展的製造能力、嚴謹的品質標準，以及數十年的專業經驗，使 CIL 成為能滿足業界不斷演變需求的可靠夥伴。」請於 10 月 28 日至 30 日蒞臨法蘭克福國際製藥原料展（CPhI Frankfurt）CIL 展位 #2.0G2，探索 ISOAPI-D —— 去氘化學推動製藥創新的未來。關於Cambridge Isotope Laboratories, Inc.CIL 為日本大塚製藥旗下子公司，是全球最大之穩定同位素及其標記化合物的製造商與供應商。自 1980 年以來，CIL 一直深受業界與學術界合作夥伴信賴，其產品廣泛應用於科研、診斷、環境監測、製藥、醫學檢測、OLED 與工業領域。CIL 的營運據點包括美國麻薩諸塞州波士頓地區的兩座設施、位於俄亥俄州錫尼亞（Xenia, OH）的大型同位素濃縮生產廠，以及 CIL 中國、CIL 加拿大、位於德國德勒斯登的 ABX（專門從事放射性同位素標記化合物，用於癌症診斷與治療），以及位於法國薩克雷（Saclay）的 Eurisotop。聯絡資訊Crissy Kriskocrissyk@isotope.com1.978.269.1930來源: Cambridge Isotope Laboratories, Inc. Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com